<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mauna Kea Technologies Sa Class O — News on 6ix</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o</link>
<description>Latest news and press releases for Mauna Kea Technologies Sa Class O on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 15:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mauna-kea-technologies-sa-class-o" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d52b7dbeedb30cb6f6b453.webp</url>
<title>Mauna Kea Technologies Sa Class O</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o</link>
</image>
<item>
<title>Mauna Kea Technologies: Publication of the 2025 Annual Financial Report</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-publication-of-the-2025-annual-financial-report</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-publication-of-the-2025-annual-financial-report</guid>
<pubDate>Thu, 30 Apr 2026 15:45:00 GMT</pubDate>
<description>PARIS & BOSTON, April 30, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that it has published its Annual Financial Report for the year ended December 31, 2025 and filed it with the Autorité des Marchés Financiers (AMF) on April 30, 2026.</description>
</item>
<item>
<title>Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio® To Be Presented at Digestive Disease Week® 2026</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-expanded-clinical-evidence-for-cellvizior-to-be-presented-at-digestive-disease-weekr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-expanded-clinical-evidence-for-cellvizior-to-be-presented-at-digestive-disease-weekr-2026</guid>
<pubDate>Tue, 28 Apr 2026 15:45:00 GMT</pubDate>
<description>PARIS & BOSTON, April 28, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today highlights its extensive clinical presence at the upcoming 2026 Digestive Disease Week® (DDW), taking place May 2-5 at McCormick Place in Chicago, Illinois. Ten Cellvizio-related abstracts accepted by DDW 2026 span four of the most clinically and commercially important areas th</description>
</item>
<item>
<title>Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-reports-fy-2025-financial-results-comprehensive-debt-restructuring-and-reaccelerating-organic-growth-mark-a-transformative-2025</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-reports-fy-2025-financial-results-comprehensive-debt-restructuring-and-reaccelerating-organic-growth-mark-a-transformative-2025</guid>
<pubDate>Wed, 22 Apr 2026 15:45:00 GMT</pubDate>
<description>PARIS & BOSTON, April 22, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its financial results for the full year ended December 31, 2025, as approved by the Board of Directors on April 21st, 2026.</description>
</item>
<item>
<title>Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-reports-strong-q1-2026-core-sales-growth</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-reports-strong-q1-2026-core-sales-growth</guid>
<pubDate>Wed, 15 Apr 2026 15:45:00 GMT</pubDate>
<description>PARIS & BOSTON, April 15, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its revenue for the first quarter of 2026.</description>
</item>
<item>
<title>Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-shares-comprising-the-share-capital</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-shares-comprising-the-share-capital</guid>
<pubDate>Wed, 08 Apr 2026 15:45:00 GMT</pubDate>
<description>PARIS, April 08, 2026--Regulatory News: Mauna Kea Technologies (Paris:ALMKT):</description>
</item>
<item>
<title>Mauna Kea Technologies Updates Its Financial Calendar</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-updates-its-financial-calendar</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-updates-its-financial-calendar</guid>
<pubDate>Tue, 17 Mar 2026 16:45:00 GMT</pubDate>
<description>PARIS & BOSTON, March 17, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the update of its financial calendar for the 2026 fiscal year.</description>
</item>
<item>
<title>Mauna Kea Technologies Announces Major Milestone for Cellvizio® in Pancreatic Cysts with CLIMB Study Selected for ASGE Presidential Plenary Session at DDW 2026</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-major-milestone-for-cellvizior-in-pancreatic-cysts-with-climb-study-selected-for-asge-presidential-plenary-session-at-ddw-2026</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-major-milestone-for-cellvizior-in-pancreatic-cysts-with-climb-study-selected-for-asge-presidential-plenary-session-at-ddw-2026</guid>
<pubDate>Wed, 11 Mar 2026 16:45:00 GMT</pubDate>
<description>PARIS & BOSTON, March 11, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today proudly announces that the CLIMB study (Confocal Laser Endomicroscopy as an IMaging Biomarker, ClinicalTrials.gov ID: NCT03492151) will be presented at the ASGE (American Society for Gastrointestinal Endoscopy) Presidential Plenary Session on Sunday, May 3, 2026, one of the most</description>
</item>
<item>
<title>Mauna Kea Technologies Accelerates International Expansion with New Regulatory Clearances in Switzerland and the United Kingdom</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-accelerates-international-expansion-with-new-regulatory-clearances-in-switzerland-and-the-united-kingdom</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-accelerates-international-expansion-with-new-regulatory-clearances-in-switzerland-and-the-united-kingdom</guid>
<pubDate>Mon, 23 Feb 2026 16:45:00 GMT</pubDate>
<description>PARIS & BOSTON, February 23, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that it has obtained the regulatory registrations and approvals required to commercialize its Cellvizio® system in Switzerland and the United Kingdom.</description>
</item>
<item>
<title>Mauna Kea Technologies Announces CE MDR Certification For Cellvizio® and Its Associated Probes</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-ce-mdr-certification-for-cellvizior-and-its-associated-probes</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-ce-mdr-certification-for-cellvizior-and-its-associated-probes</guid>
<pubDate>Tue, 10 Feb 2026 16:45:00 GMT</pubDate>
<description>PARIS & BOSTON, February 10, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that it has received certification of conformity to the European Medical Device Regulation (MDR 2017/745) for its entire Cellvizio system and range of probes.</description>
</item>
<item>
<title>Mauna Kea Technologies Announces New Commercial Organization to Accelerate Growth Outside the United States</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-new-commercial-organization-to-accelerate-growth-outside-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-new-commercial-organization-to-accelerate-growth-outside-the-united-states</guid>
<pubDate>Wed, 04 Feb 2026 16:45:00 GMT</pubDate>
<description>PARIS & BOSTON, February 04, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced key organizational changes to drive accelerated growth outside the United States. These moves build directly on the strong 2025 sales performance positioning the Company with two major growth drivers: pancreatic cysts and CellTolerance® (detection of food intoleran</description>
</item>
<item>
<title>Mauna Kea Technologies Announces Initiation of Coverage by Allinvest Securities</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-initiation-of-coverage-by-allinvest-securities</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-initiation-of-coverage-by-allinvest-securities</guid>
<pubDate>Mon, 26 Jan 2026 17:08:00 GMT</pubDate>
<description>PARIS & BOSTON, January 26, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) announces today the initiation of coverage of its stock by the financial research firm Allinvest Securities.</description>
</item>
<item>
<title>Mauna Kea Technologies Announces Its 2026 Financial Calendar Highlighted by Its Participation in Several Investor Forums</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-its-2026-financial-calendar-highlighted-by-its-participation-in-several-investor-forums</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-its-2026-financial-calendar-highlighted-by-its-participation-in-several-investor-forums</guid>
<pubDate>Wed, 21 Jan 2026 16:45:00 GMT</pubDate>
<description>PARIS & BOSTON, January 21, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces its financial calendar for the 2026 fiscal year as well as the resumption of its participation in investor conferences.</description>
</item>
<item>
<title>Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S.</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-reports-strong-q4-2025-sales-driven-by-accelerated-growth-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-reports-strong-q4-2025-sales-driven-by-accelerated-growth-in-the-us</guid>
<pubDate>Thu, 15 Jan 2026 16:45:00 GMT</pubDate>
<description>PARIS & BOSTON, January 15, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its revenue for the fourth quarter of 2025.</description>
</item>
<item>
<title>Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-and-taewoong-medical-usa-announce-exclusive-partnership-to-accelerate-commercial-expansion-in-the-us-in-pancreatic-cyst-management</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-and-taewoong-medical-usa-announce-exclusive-partnership-to-accelerate-commercial-expansion-in-the-us-in-pancreatic-cyst-management</guid>
<pubDate>Wed, 03 Dec 2025 17:00:00 GMT</pubDate>
<description>LOS ANGELES & PARIS & BOSTON, December 03, 2025--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform and TaeWoong Medical USA, a leader in minimally invasive gastrointestinal (GI) diagnostic and therapeutic EUS guided solutions, today announced the signing of an exclusive partnership in the United States to bring physicians and hospitals the industry’s first fully in</description>
</item>
<item>
<title>Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio® Platform</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-receives-nmpa-regulatory-approval-in-china-for-its-next-generation-cellvizior-platform</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-receives-nmpa-regulatory-approval-in-china-for-its-next-generation-cellvizior-platform</guid>
<pubDate>Thu, 20 Nov 2025 16:45:00 GMT</pubDate>
<description>PARIS & BOSTON, November 20, 2025--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that it has obtained approval from the National Medical Products Administration (NMPA) in China for the import and commercialization of its next-generation Cellvizio (Gen 3) platform.</description>
</item>
<item>
<title>Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-the-successful-completion-of-its-financial-restructuring-and-euro6m-capital-raise</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-the-successful-completion-of-its-financial-restructuring-and-euro6m-capital-raise</guid>
<pubDate>Fri, 14 Nov 2025 06:45:00 GMT</pubDate>
<description>PARIS & BOSTON, November 14, 2025--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (the "Company"), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the full success of its financial restructuring and of its capital increase (the "Operation"), launched yesterday following the approval of its safeguard plan (the "Plan") by the Paris Court of Economic Activities (Tribunal des Activités Économiques</description>
</item>
<item>
<title>Mauna Kea Technologies Exits Safeguard Proceedings Following Court Approval of its Plan and Initiates Minimum €5M Capital Raise</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-exits-safeguard-proceedings-following-court-approval-of-its-plan-and-initiates-minimum-euro5m-capital-raise</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-exits-safeguard-proceedings-following-court-approval-of-its-plan-and-initiates-minimum-euro5m-capital-raise</guid>
<pubDate>Thu, 13 Nov 2025 06:45:00 GMT</pubDate>
<description>PARIS & BOSTON, November 13, 2025--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that, by a judgment rendered on November 12, 2025, the Paris Commercial Court (the "Court") has approved its safeguard plan (the "Plan") presented during the hearing of October 27, 2025.</description>
</item>
<item>
<title>Mauna Kea Technologies Announces It Has Secured Over €5M in Firm Subscription Commitments as Required for Its Capital Increase</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-it-has-secured-over-euro5m-in-firm-subscription-commitments-as-required-for-its-capital-increase</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-it-has-secured-over-euro5m-in-firm-subscription-commitments-as-required-for-its-capital-increase</guid>
<pubDate>Tue, 21 Oct 2025 15:45:00 GMT</pubDate>
<description>PARIS & BOSTON, October 21, 2025--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announced it has secured firm subscription commitments for an amount exceeding €5 million, corresponding to the minimum target set by its draft safeguard plan (the "Safeguard Plan").</description>
</item>
<item>
<title>Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-reports-third-quarter-2025-revenue-up-16percent-at-constant-exchange-rates</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-reports-third-quarter-2025-revenue-up-16percent-at-constant-exchange-rates</guid>
<pubDate>Mon, 13 Oct 2025 15:45:00 GMT</pubDate>
<description>PARIS & BOSTON, October 13, 2025--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced its revenue for the third quarter of 2025, up 16% at constant exchange rates (CER).</description>
</item>
<item>
<title>Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan</title>
<link>https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-the-terms-of-its-financing-under-its-safeguard-plan</link>
<guid isPermaLink="true">https://6ix.com/company/mauna-kea-technologies-sa-class-o/news/mauna-kea-technologies-announces-the-terms-of-its-financing-under-its-safeguard-plan</guid>
<pubDate>Wed, 08 Oct 2025 15:45:00 GMT</pubDate>
<description>PARIS & BOSTON, October 08, 2025--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today specifies the terms of its proposed capital increase (the "Capital Increase") as part of its safeguard plan, which was approved by a majority of the classes of affected parties as announced on October 6.</description>
</item>
</channel>
</rss>